Boell, Boris, Goergen, Helen, Behringer, Karolin, Broeckelmann, Paul J., Hitz, Felicitas, Kerkhoff, Andrea, Greil, Richard, von Tresckow, Bastian, Eichenauer, Dennis A., Buerkle, Carolin, Borchmann, Sven, Fuchs, Michael, Diehl, Volker, Engert, Andreas and Borchmann, Peter (2016). Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials. Blood, 127 (18). S. 2189 - 2193. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Full text not available from this repository.

Abstract

Doxorubicin, bleomycin, vinblastine sulfate, and dacarbazine (ABVD) is associated with severe toxicity in older patients, particularly from bleomycin-induced lung toxicity (BLT). Therefore, using bleomycin has been questioned in older Hodgkin lymphoma (HL) patients, especially in early-stage HL. We therefore analyzed feasibility, toxicity, and efficacy of ABVD or AVD in 287 older early-stage favorable HL patients. We included patients >= 60 years of age in the German Hodgkin Study Group HD10 and HD13 trials randomized to either 2 cycles of ABVD (2xABVD; n=137) or AVD (2xAVD; n=82), each followed by involved-field radiotherapy (IF-RT), with patients randomized to 4xABVD+IF-RT (n=68). Patients' median age was 65 years (range, 60-75) with comparable patient and disease characteristics. Grade III-IV adverse event rates were similar in patients receiving 2xAVD and 2xABVD (40% and 39%, respectively), but considerably higher in patients receiving 4xABVD (65%). Similarly, BLT was rare in patients receiving 2xABVD/AVD, but occurred in 7/69 (10%) of patients randomized to 4xABVD, with 3 lethal events. In conclusion, no effects of bleomycin on toxicity rates were detectable in older patients receiving 2 cycles of chemotherapy. However, we found a high risk of severe toxicity of bleomycin in older HL patients receiving more than 2 cycles of ABVD. These trials are registered at www.clinicaltrials.gov and www.isrctn.com as #NCT00265018 (HD10) and #ISRCTN63474366 (HD13).

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Boell, BorisUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Goergen, HelenUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Behringer, KarolinUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Broeckelmann, Paul J.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Hitz, FelicitasUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kerkhoff, AndreaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Greil, RichardUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
von Tresckow, BastianUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Eichenauer, Dennis A.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Buerkle, CarolinUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Borchmann, SvenUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Fuchs, MichaelUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Diehl, VolkerUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Engert, AndreasUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Borchmann, PeterUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-275869
DOI: 10.1182/blood-2015-11-681064
Journal or Publication Title: Blood
Volume: 127
Number: 18
Page Range: S. 2189 - 2193
Date: 2016
Publisher: AMER SOC HEMATOLOGY
Place of Publication: WASHINGTON
ISSN: 1528-0020
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
ELDERLY-PATIENTS; ABVD; VINBLASTINE; DACARBAZINE; ADRIAMYCIN; PREDNISONE; PHASE-2; REGIMEN; LINEMultiple languages
HematologyMultiple languages
Refereed: Yes
URI: http://kups.ub.uni-koeln.de/id/eprint/27586

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item